Feng et al. (2014) observed that PARP1 inhibitors induced varying levels of radiosensitization across different breast cancer cell lines, irrespective of the breast cancer subtype or the presence of BRCA1 gene mutation. This evidence concerns the gene PARP1 and breast cancer.